Company Performance - Astria Therapeutics, Inc. (ATXS) has gained approximately 25.9% year-to-date, significantly outperforming the Medical sector, which has returned an average of -2.7% [4] - The Zacks Consensus Estimate for ATXS' full-year earnings has increased by 4.5% over the past 90 days, indicating improving analyst sentiment and a positive earnings outlook [3] Industry Comparison - Astria Therapeutics, Inc. is part of the Medical - Biomedical and Genetics industry, which includes 501 individual stocks and currently ranks 69 in the Zacks Industry Rank. This industry has seen an average loss of 9.7% this year, highlighting ATXS's superior performance [5] - In contrast, Abbott (ABT), another stock in the Medical sector, has a year-to-date return of 2.3% and belongs to the Medical - Products industry, which is ranked 85 and has moved up by 11.4% year-to-date [4][6] Sector Overview - The Medical sector consists of 1021 individual stocks and currently holds a Zacks Sector Rank of 3, which measures the strength of the sector groups based on the average Zacks Rank of individual stocks [2] - The Zacks Rank system emphasizes earnings estimates and revisions, with ATXS currently holding a Zacks Rank of 2 (Buy), indicating a favorable outlook compared to the broader market [3]
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?